Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03258320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 1 to Phase 2/3
    • Enrollment target: 50 to 300
    v9
  2. Eligibility criteria expanded, about 1 word
    • Study title shortened, about 2 words
    v8
  3. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: Dec 2025 to Dec 2027
    v7
  4. Primary completion date: Dec 2022 to Dec 2024
    • Study completion date: Dec 2023 to Dec 2025
    v6
  5. Primary completion date: Jul 2020 to Dec 2022
    • Study completion date: Dec 2021 to Dec 2023
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Jul 2019 to Jul 2020
    • Study completion date: Dec 2020 to Dec 2021
    v4
  2. Study title expanded, about 4 wordsv3
  3. Study description revisedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer (CRPC), which is finally refractory to most modalities of clinical intervention with a clinically lethal nature.
Trial Details
NCT Number NCT03258320
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Fudan University, Qilu Hospital of Shandong University
Conditions
(from sponsor)		 Prostate Cancer Patients
Related terms Prostatic Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov